The Quantellect read.As of Nov 19, 2026, 10 active firms cover Allogene Therapeutics Inc: 7 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $3.85 to $14.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.19 sits 1072% above the current $0.70. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 80215% next, consensus EPS building from about $-0.14 next quarter toward $-0.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy770%
Neutral330%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.19
+1071.7% upside
Average target across 9 active firms as of Nov 19, 2026 vs $0.70 current
Highest Target$14.00
Average Target$8.19
Lowest Target$3.85
Detailed analyst forecasts for ALLO
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 7 of 10 active firms rate ALLO a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ALLO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.17 – $-0.09 · 4 analysts · -22% YoY
Next period, 4 analysts expect Allogene Therapeutics Inc to earn $-0.14 a share (range $-0.17 – $-0.09), versus $-0.18 a year earlier. Full-year consensus is $-0.58, growing to $-0.61 the year after.
REVENUE · NEXT QUARTER
$3.3K
Range $0 – $20.0K · 4 analysts · +0% YoY
Revenue is expected to reach $3.3K (range $0 – $20.0K), +0.0% year-over-year. Full-year consensus is $3.8M, rising to $10.6M next year.
Top analysts covering Allogene Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALLO.
#1
Luca Issi
RBC Capital · Rank #76
Buy
$9.00+1187.7% to target
Overall win rate
49%
+ Follow
#2
Brian Cheng
JP Morgan · Rank #87
Neutral
No targeton ALLO
Overall win rate
51%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$10.00+1330.8% to target
Overall win rate
43%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$11.00+1473.9% to target
Overall win rate
42%
+ Follow
#5
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$4.00+472.3% to target
Overall win rate
41%
+ Follow
ALLO stock forecast FAQ
What is ALLO's average 12-month price target?+
The 9 active firms with a live target average $8.19 for Allogene Therapeutics Inc over the next 12 months, ranging from a $14.00 high to a $3.85 low, as of Nov 19, 2026.
Is ALLO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ALLO?+
The Street-high target is $14.00 (Canaccord Genuity), and the Street-low is $3.85 (Bernstein). The average of all 9 active-firm targets is $8.19.
How many active Wall Street firms cover ALLO?+
10 active firms have a recognized rating on Allogene Therapeutics Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ALLO?+
Among analysts who currently cover ALLO, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Buy with a $9.00 target.
What is Allogene Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.17 – $-0.09) across 4 analysts. Full-year EPS is projected at $-0.58, rising to $-0.61 the following year.
How much revenue is Allogene Therapeutics Inc expected to report next quarter?+
Consensus revenue is $3.3K (range $0 – $20.0K). Full-year revenue is projected at $3.8M, growing to $10.6M next year.
Have analysts been upgrading or downgrading ALLO lately?+
As of Nov 19, 2026, 7 of 10 active firms rate ALLO a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALLO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.